Archive

• 2023
  • Join us! We are hiring both a Senior Scientist and a Scientist
  • Guest editor for Stockholm Science City on Instagram
• 2022
  • Scandinavian Biopharma donates mosquito nets to orphanages in Benin – a gift that saves lives
  • New ETVAX® data was presented during VASE, an international gathering dedicated to develop Shigella and ETEC vaccines
  • Scandinavian Biopharma welcomes Johan Jarmander to the position as Drug Substance Specialist Manufacturing & Development
  • Scandinavian Biopharma enters into a commercial collaboration with Novavax in Sweden
  • Scandinavian Biopharma has successfully completed the enrolment of their large Phase IIb trial in The Gambia
  • We continue to expand and welcome Marja Held as Senior Regulatory Affairs Manager
  • Scandinavian Biopharma welcomes Anna Sumic to the position as Drug Substance and Drug Product Manufacturing Specialist
  • We are looking for a Clinical Project Manager
  • 10/10 Marks A Day to Bring Awareness to One of The Rarest Bleeding Disorders
  • Read about our ETEC Vaccine development in the Annual Report from EDCTP
  • Scandinavian Biopharma announces marketing and distribution agreement with Emergent to relaunch the oral typhoid vaccine (Ty21a) in Germany
  • Scandinavian Biopharma extends its agreement with USAMMDA and obtains additional financial support
  • Scandinavian Biopharma recruits Agneta Lissmats as Senior Director Biostatistics
  • Scandinavian Biopharma made important progress in research, set a new sales record and strengthened the organization in 2021
  • Scandinavian Biopharma welcomes Sara Grahm to the position as Director of Manufacturing
  • Scandinavian Biopharma welcomes Maria Edlund to the position as Drug Product Manufacturing Specialist
  • Scandinavian Biopharma continuous the tradition of donating food to orphanages in Grand Popo, Benin!
  • Scandinavian Biopharma’s expansion requires expanded premises
  • Scandinavian Biopharma strengthens its vaccine portfolio in the field of diarrhoeal disease by in-licencing a Campylobacter vaccine technology from Canadian company, VaxAlta Inc.
• 2021
  • An improved formulation of Scandinavian Bioharmas ETEC vaccine candidate is currently being tested in an immunogenicity bridging study
  • We welcome Aino Råberg as Drug Substance Lead Manufacturing at Scandinavian Biopharma
  • New ETVAX® data will be presented during VASE, a conference designed to spark innovation and accelerate the momentum for research and development on enteric vaccines
  • We welcome Camilla Jidling – our new QA Manager
  • Scandinavian Biopharma is growing and we now welcome Maria Fernanda Ehrman
  • Welcome Günes Uysal
  • We are delighted to be highlighted in the science and innovation magazine, EU Research magazine, from the European Union
  • We are proud to be part of the fight against malaria through our collaboration with Care Plus®
  • Scandinavian Biopharma shows strong financial results for the pandemic year 2020
  • Scandinavian Biopharma is present at Nordic Life Science Days
  • Susanne Ellfors-Zetterlund new Chief Medical Officer (CMO) at Scandinavian Biopharma
  • The first children have been vaccinated in Scandinavian Biopharma’s large Phase IIb study in The Gambia
  • We welcome Tomas Danielsson as Senior Project Manager Manufacturing at Scandinavian Biopharma
  • Telia has chosen to highlight us in their promotion campaign
  • Scandinavian Biopharma’s clinical phase IIb study in Benin has become a documentary
• 2020
  • We continue to expand and welcome Catharina Forzelius as our Program Director
  • Scandinavian Biopharma recruits Christin Hindrika Strid as Clinical Operations Manager
  • We continue to expand and welcome Åsa Dahlbäck as VP Regulatory Affairs
  • EY Announces Scandinavian Biopharma CEO and founder, Björn Sjöstrand, as a Stockholm finalist for the prestigious ‘Entrepreneur Of The Year’ award
  • Scandinavian Biopharma provides seasonal gifts already during the beginning of November because of the pandemic
  • The World Health Organization concludes that ETEC remains a priority pathogen and is encouraged by our preliminary phase 2B results from Benin
  • Scandinavian Biopharma enters into Agreement with USAMRAA to facilitate the development of the oral vaccine ETVAX® against travellers’ diarrhoea
  • Scandinavian Biopharma continues to expand and welcomes Erika Söderström as Key Account Manager
  • Scandinavian Biopharma has successfully completed the enrolment of the clinical Phase 1 trial in Zambia
  • We continue to expand and welcome Robert Lindberg
  • Scandinavian Biopharma expand their portfolio with Coagadex® – the first and only tailormade treatment for the rare bleeding disorder ‘factor X deficiency’
  • Promising preliminary findings from a Phase 2b study of the oral vaccine ETVAX® against travelers’ diarrhea in Finnish travelers to Benin, West Africa
  • Scandinavian Biopharma recruits Anna Hill as Clinical Operations Manager
  • The science is clear – let us highlight and support ‘World Immunization Week’
  • Scandinavian Biopharma is once again looking back on a very successful business year
  • Welcome Morgan Hjorth
  • Scandinavian Biopharma secures €10.6 million from EDCTP for a Phase III trial of ETVAX® in children in low- and middle-income countries
  • Scandinavian Biopharma expands its Nordic vaccine business with the oral typhoid vaccine Vivotif®
• 2019
  • Christine Källén joins Scandinavian Biopharma as our new VP Quality Assurance
  • Scandinavian Biopharma Wishes Happy Holidays by donating food, medicines and mattresses to several orphanages in Benin!
  • Scandinavian Biopharma reports successful results of the oral, inactivated ETEC vaccine candidate ETVAX® against enterotoxigenic E. coli diarrhoea in a placebo-controlled phase I/II study in infants and children from 6 months to 5 years of age in Bangladesh
  • The successful immunogenicity and safety results of ETVAX® are presented at Vaccines for Enteric Diseases (VED) Oct 16-18 in Lausanne, Switzerland
  • Scandinavian Biopharma awarded and qualified “Gazelle Company” by Dagens Industri
  • We are one of the Biotech Company of the Year finalists at the 2019 European Lifestars Awards!
  • We have successfully completed the enrolment of the first cohort including 40 adults in our study in Zambia
  • Scandinavian Biopharma is launching an updated brand identity
  • Scandinavian Biopharma announces great progress in the development of ETVAX® as well as a strong organic growth for the distribution business
  • Scandinavian Biopharma welcomes Dilek Merdol as new head of Quality Control (QC)
  • Scandinavian Biopharma announces the last follow up visit in the phase IIB clinical trial with ETVAX® in Finnish travellers to Benin
  • Scandinavian Biopharma officially starts their late phase development program in Africa funded by EDCTP
  • Scandinavian Biopharma recruits Madelene Franzén as Accounting Manager
  • Scandinavian Biopharma has been awarded 7.4 million EUR from the EU for clinical trials of ETVAX® – a unique and newly developed vaccine against diarrheal disease
• 2018
  • Scandinavian Biopharma Wishes Happy Holidays by donating food to an orphanage in Grand Popo, Benin!
  • Tomas Åslund joins Scandinavian Biopharma as VP Manufacturing
  • The Entrepreneur of the Year in Solna
  • Our collaboration partner, Jan Holmgren, is receiving the world’s biggest award in the field of global health
  • Scandinavian Biopharma awarded the Swedish national tender for the TdaP booster vaccine
  • We are proud to be “2018 Distributor of the year”
  • Sweden’s ambassador Annika Thunborg attended the VASE conference in Mexico City
  • We want to raise awareness
  • New ETVAX® data will be presented during Vaccines Against Shigella and ETEC (VASE) conference in Mexico
  • Kyoko Misawa joins Scandinavian Biopharma as Clinical study manager
  • Scandinavian Biopharma is once again looking back on a highly successful business year
  • Our Phase IIB study on the BBC news!
  • Meet Scandinavian Biopharma at Northern European Conference on Travel Medicine (NECTM 7) in Stockholm
  • Scandinavian Biopharma gets support by the County Administrative Board in Stockholm
  • Guest editor for Stockholm Science City on Instagram
  • Our vaccine project on PATH´s DefeatDD Blog
  • Welcome to Scandinavian Biopharma,
• 2017
  • Charlotte Flodin joins Scandinavian Biopharma as VP Quality Assurance
  • Jonas Bengtsson joins Scandinavian Biopharma as VP Business Development and International Sales
  • New ETVAX® data will be presented during Vaccines for Enteric Diseases (VED) conference
  • We look forward seeing you at Nordic Life Science Days
  • Scandinavian Biopharma continues to grow – 2016 was another successful year
  • Our collaboration partner, Jan Holmgren, is awarded the world’s greatest vaccine prize
  • Scandinavian Biopharma enters into an exclusive agreement with Flynn Pharma for ViperaTAb
  • Scandinavian Biopharma is expanding by hiring a PhD in cell- and molecular biology
  • All 450 participants starting from adults down to 6 months young infants are enrolled in our study in Bangladesh
• 2016
  • We are proud!
  • Etvax® was presented at VASE Conference
• 2015
  • Our ETEC-story is told in ”European Biotechnology”
  • ETVAX® was presented at ASTMH in Philadelphia
  • Scandinavian Biopharma expands its product portfolio with an immunosuppressive drug
  • Scandinavian Biopharma announces first patient vaccinated in the age-descending study in Bangladesh
  • ETVAX® was presented as the lead candidate at CISTM14
  • Scandinavian Biopharma and PATH sign amendment to collaborative agreement to develop a vaccine against diarrhoeal disease
• 2014
  • Impressive results in new Vaccine publication
  • Mapping the spread of diarrheal bacteria supports the design of our new vaccine
  • Our story is told in a new editorial book
  • Scandinavian Biopharma receives 4.5 MSEK in funding from Vinnova
  • Etvax® is now a registered trademark
  • Scandinavian Biopharma is expanding by hiring a pharmacist, PhD in microbiology
  • Scandinavian Biopharma – A Fast Growing Swedish biotech company
• 2013
  • Scandinavian Biopharma and PATH sign collaborative development agreement after successful Phase I study of a novel vaccine candidate against diarrheal disease.
  • Phase I results will be presented at the International Conference on Mucosal Vaccines, Adjuvants & Delivery, in Copenhagen
  • Scandinavian Biopharma announces successful results in placebo-controlled Phase I study of an oral, inactivated vaccine against diarrhea for travelers and children in developing countries
  • Preclinical studies of the new oral Traveler’s diarrhea vaccine shows that it is safe and immunogenic
  • Scandinavian Biopharma through its subsidiary ETVAX continues clinical development
• 2012
  • Pressrelease – Scandinavian Biopharma announces positive results from its phase I study of a traveler’s diarrhea vaccine
  • PerioPruvTM-Point of Care Rapid test for Periodontal Infection

Press